This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Oct 1;29(10):2143.

doi: 10.1093/annonc/mdy261.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

A K Krug¹, D Enderle¹, C Karlovich², T Priewasser¹, S Bentink¹, A Spiel¹, K Brinkmann¹, J Emenegger¹, D G Grimm¹, E Castellanos-Rizaldos³, J W Goldman⁴, L V Sequist⁵, J-C Soria⁶, D R Camidge⁷, S M Gadgeel⁸, H A Wakelee⁹, M Raponi², M Noerholm¹, J Skog¹⁰

Affiliations

Affiliations

¹ Exosome Diagnostics GmbH, Martinsried, Germany.
² Clovis Oncology Inc., San Francisco, USA.
³ Exosome Diagnostics, Waltham, USA.
⁴ University of California Los Angeles, Los Angeles, USA.
⁵ Massachusetts General Hospital, Boston, USA.
⁶ Institut Gustave Roussy, Villejuif, France; University Paris-Sud, Paris, France.
⁷ University of Colorado, Denver, USA.
⁸ Karmanos Cancer Institute/Wayne State University, Detroit, USA.
⁹ Stanford University, Stanford, USA.
¹⁰ Exosome Diagnostics, Waltham, USA. Electronic address: johan@exosomedx.com.

PMID: 30060089
DOI: 10.1093/annonc/mdy261

Free article

Comment

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma

A K Krug et al. Ann Oncol. 2018.

Free article

. 2018 Oct 1;29(10):2143.

doi: 10.1093/annonc/mdy261.

Authors

A K Krug¹, D Enderle¹, C Karlovich², T Priewasser¹, S Bentink¹, A Spiel¹, K Brinkmann¹, J Emenegger¹, D G Grimm¹, E Castellanos-Rizaldos³, J W Goldman⁴, L V Sequist⁵, J-C Soria⁶, D R Camidge⁷, S M Gadgeel⁸, H A Wakelee⁹, M Raponi², M Noerholm¹, J Skog¹⁰

Affiliations

¹ Exosome Diagnostics GmbH, Martinsried, Germany.
² Clovis Oncology Inc., San Francisco, USA.
³ Exosome Diagnostics, Waltham, USA.
⁴ University of California Los Angeles, Los Angeles, USA.
⁵ Massachusetts General Hospital, Boston, USA.
⁶ Institut Gustave Roussy, Villejuif, France; University Paris-Sud, Paris, France.
⁷ University of Colorado, Denver, USA.
⁸ Karmanos Cancer Institute/Wayne State University, Detroit, USA.
⁹ Stanford University, Stanford, USA.
¹⁰ Exosome Diagnostics, Waltham, USA. Electronic address: johan@exosomedx.com.

PMID: 30060089
DOI: 10.1093/annonc/mdy261

No abstract available

PubMed Disclaimer

Comment on

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.
Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J. Krug AK, et al. Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765. Ann Oncol. 2018. PMID: 29216356 Free PMC article. Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal